Neonatal Survival After Serial Amnioinfusions for Bilateral Renal Agenesis: The Renal Anhydramnios Fetal Therapy Trial
- PMID: 38051327
- PMCID: PMC10698620
- DOI: 10.1001/jama.2023.21153
Neonatal Survival After Serial Amnioinfusions for Bilateral Renal Agenesis: The Renal Anhydramnios Fetal Therapy Trial
Abstract
Importance: Early anhydramnios during pregnancy, resulting from fetal bilateral renal agenesis, causes lethal pulmonary hypoplasia in neonates. Restoring amniotic fluid via serial amnioinfusions may promote lung development, enabling survival.
Objective: To assess neonatal outcomes of serial amnioinfusions initiated before 26 weeks' gestation to mitigate lethal pulmonary hypoplasia.
Design, setting, and participants: Prospective, nonrandomized clinical trial conducted at 9 US fetal therapy centers between December 2018 and July 2022. Outcomes are reported for 21 maternal-fetal pairs with confirmed anhydramnios due to isolated fetal bilateral renal agenesis without other identified congenital anomalies.
Exposure: Enrolled participants initiated ultrasound-guided percutaneous amnioinfusions of isotonic fluid before 26 weeks' gestation, with frequency of infusions individualized to maintain normal amniotic fluid levels for gestational age.
Main outcomes and measures: The primary end point was postnatal infant survival to 14 days of life or longer with dialysis access placement.
Results: The trial was stopped early based on an interim analysis of 18 maternal-fetal pairs given concern about neonatal morbidity and mortality beyond the primary end point despite demonstration of the efficacy of the intervention. There were 17 live births (94%), with a median gestational age at delivery of 32 weeks, 4 days (IQR, 32-34 weeks). All participants delivered prior to 37 weeks' gestation. The primary outcome was achieved in 14 (82%) of 17 live-born infants (95% CI, 44%-99%). Factors associated with survival to the primary outcome included a higher number of amnioinfusions (P = .01), gestational age greater than 32 weeks (P = .005), and higher birth weight (P = .03). Only 6 (35%) of the 17 neonates born alive survived to hospital discharge while receiving peritoneal dialysis at a median age of 24 weeks of life (range, 12-32 weeks).
Conclusions and relevance: Serial amnioinfusions mitigated lethal pulmonary hypoplasia but were associated with preterm delivery. The lower rate of survival to discharge highlights the additional mortality burden independent of lung function. Additional long-term data are needed to fully characterize the outcomes in surviving neonates and assess the morbidity and mortality burden.
Trial registration: ClinicalTrials.gov Identifier: NCT03101891.
Conflict of interest statement
Figures
Comment in
-
Bilateral Renal Agenesis-Interpreting the RAFT Trial.JAMA. 2023 Dec 5;330(21):2059-2060. doi: 10.1001/jama.2023.22747. JAMA. 2023. PMID: 38051335 No abstract available.
Similar articles
-
Design and Protocol of the Renal Anhydramnios Fetal Therapy (RAFT) Trial.Clin Ther. 2022 Aug;44(8):1161-1171. doi: 10.1016/j.clinthera.2022.07.001. Epub 2022 Jul 30. Clin Ther. 2022. PMID: 35918190 Free PMC article. Clinical Trial.
-
Role of amnioinfusion in the management of premature rupture of the membranes at <26 weeks' gestation.Am J Obstet Gynecol. 2000 Oct;183(4):878-82. doi: 10.1067/mob.2000.108873. Am J Obstet Gynecol. 2000. PMID: 11035330
-
Etiology and management of early pregnancy renal anhydramnios: Is there a place for serial amnioinfusions?Prenat Diagn. 2020 Apr;40(5):528-537. doi: 10.1002/pd.5658. Epub 2020 Feb 19. Prenat Diagn. 2020. PMID: 32003482 Free PMC article. Review.
-
Amnioinfusions to Treat Early Onset Anhydramnios Caused by Renal Anomalies: Background and Rationale for the Renal Anhydramnios Fetal Therapy Trial.Fetal Diagn Ther. 2019;45(6):365-372. doi: 10.1159/000497472. Epub 2019 Mar 21. Fetal Diagn Ther. 2019. PMID: 30897573 Free PMC article.
-
Fetal Therapy for Renal Anhydramnios.Clin Perinatol. 2022 Dec;49(4):849-862. doi: 10.1016/j.clp.2022.08.001. Epub 2022 Oct 9. Clin Perinatol. 2022. PMID: 36328603 Review.
Cited by
-
First fetus-to-fetus transplant demonstrated in rats.Nature. 2024 May;629(8011):267-268. doi: 10.1038/d41586-024-01152-y. Nature. 2024. PMID: 38689127 No abstract available.
-
The genetic etiologies of bilateral renal agenesis.Prenat Diagn. 2024 Feb;44(2):205-221. doi: 10.1002/pd.6516. Epub 2024 Jan 5. Prenat Diagn. 2024. PMID: 38180355 Review.
-
Precarious hope: Ethical considerations for offering experimental fetal therapies outside of research after initial studies in humans.Prenat Diagn. 2024 Feb;44(2):180-186. doi: 10.1002/pd.6474. Epub 2023 Dec 9. Prenat Diagn. 2024. PMID: 38069681